AstraZeneca, Amgen Report Phase III Results For TEZSPIRE In Eosinophilic Esophagitis; TEZSPIRE Meets Key Endpoints In Phase III CROSSING Trial
In brief
TEZSPIRE’s Phase III trial shows sustained, clinically meaningful benefits in EoE, supporting its future development and market potential.